ID   SBC-3/CDDP
AC   CVCL_M842
DR   Wikidata; Q54952171
RX   PubMed=9227790;
RX   PubMed=9615743;
RX   PubMed=10628341;
CC   Population: Japanese.
CC   Doubling time: 27.5 hours (PubMed=9615743; PubMed=10628341).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1678 ! SBC-3
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 13
//
RX   PubMed=9227790; DOI=10.18926/AMO/30795;
RA   Matsuo K., Kiura K., Ueoka H., Tabata M., Shibayama T., Matsumura T.,
RA   Takigawa N., Hiraki S., Harada M.;
RT   "Growth inhibitory effects of antifolates against an
RT   adriamycin-resistant human small cell lung cancer cell line.";
RL   Acta Med. Okayama 51:121-127(1997).
//
RX   PubMed=9615743;
RA   Moritaka T., Kiura K., Ueoka H., Tabata M., Segawa Y., Shibayama T.,
RA   Takigawa N., Ohnoshi T., Harada M.;
RT   "Cisplatin-resistant human small cell lung cancer cell line shows
RT   collateral sensitivity to vinca alkaloids.";
RL   Anticancer Res. 18:927-933(1998).
//
RX   PubMed=10628341;
RA   Ikubo S., Takigawa N., Ueoka H., Kiura K., Tabata M., Shibayama T.,
RA   Chikamori M., Aoe K., Matsushita A., Harada M.;
RT   "In vitro evaluation of antimicrotubule agents in human small-cell
RT   lung cancer cell lines.";
RL   Anticancer Res. 19:3985-3988(1999).
//